GC Cell Presents GCC2005 Phase 1a Results at ICBMT 2026

GC Cell reported interim Phase 1a results for CAR-NK therapy GCC2005 at ICBMT 2026 in Busan. In 8 of 9 patients with relapsed or refractory NK/T-cell lymphoma, the objective response rate was 62.5%, including 3 complete remissions; one patient remains in remission at 18 months.

• ORR 62.5%: 3 complete and 2 partial remissions in 8 patients
• No cases of ICANS or GvHD reported
• AITL patient in complete remission 18 months after low dose
• Company completed Phase 1a and is preparing Phase 1b